# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0192 |
| Population Package | PP-0192 |
| Title | Biomarker Testing for Immunotherapy |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Last Updated | 2026-08-09 |

---

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| Single educational question | PASS | The package answers which biomarker testing is relevant when immunotherapy is being considered for gastric adenocarcinoma. |
| Scope respected | PASS | Testing strategy is central; detailed biomarker testing and treatment selection remain outside ownership. |
| Complete coverage | PASS | Purpose, predictive biomarker concept, PD-L1, MSI/MMR, TMB, NGS, EBV, interacting biomarkers, timing, specimen, adequacy, result meaning and downstream transition are covered. |
| Internal consistency | PASS | PD-L1 and MSI/MMR are consistently treated as complementary core domains; TMB/NGS are consistently treated as selected broader testing considerations. |
| Logical organization | PASS | Content follows clinical question → biomarker purpose → core biomarkers → broader testing → contextual biomarkers → testing context → result meaning → downstream application. |
| Knowledge blocks complete | PASS | Independent patient-facing blocks are used throughout. |
| Common misconceptions addressed | PASS | Negative results, inadequate tests, PD-L1, MSI/MMR, TMB, NGS and treatment guarantees are addressed. |
| Patient-facing questions included | PASS | Practical questions for discussion with the cancer care team are included. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream PPs are defined. |
| Adjacent PP overlap controlled | PASS | Dedicated biomarker packages and downstream treatment packages retain substantive ownership. |

---

# Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| Scientifically accurate within source-supported scope | PASS | Claims are grounded in supplied NCCN, NCI, ACS and ESMO-ASCO materials. |
| Consistent with NCCN gastric-cancer guidance | PASS | Universal MSI/MMR testing, PD-L1 testing framework, NGS/TMB context, specimen concepts and treatment-context statements follow supplied NCCN v2.2026 material. |
| Consistent with NCI patient-facing treatment context | PASS | Biomarker testing is described as information that may help predict response to immunotherapy. |
| Consistent with ACS patient-facing context | PASS | PD-L1 and MSI-H/dMMR treatment relevance is represented without converting ACS examples into individualized recommendations. |
| Consistent with ESMO-ASCO framework | PASS | Biomarker testing is positioned within broader precision oncology and clinical-context interpretation. |
| No unsupported clinical claim | PASS | Emerging or context-dependent topics are explicitly qualified. |
| No unsafe medical advice | PASS | No individualized treatment or treatment-change instruction is provided. |
| PD-L1 appropriately qualified | PASS | PD-L1 is treated as a core testing domain while detailed scoring and interpretation are delegated. |
| MSI/MMR appropriately qualified | PASS | MSI/MMR is treated as a core testing domain with detailed methodology delegated. |
| TMB appropriately qualified | PASS | TMB is not presented as equivalent to universal PD-L1/MSI/MMR testing. |
| NGS appropriately qualified | PASS | NGS is treated as a broader testing platform, not as a single biomarker. |
| EBV appropriately qualified | PASS | EBV is identified as emerging/non-routine rather than a universal immunotherapy biomarker. |
| HER2/CLDN18.2 appropriately bounded | PASS | These biomarkers are presented as other treatment-relevant biomarkers, not as core immunotherapy biomarkers. |
| Negative-result interpretation appropriately qualified | PASS | Negative is distinguished from inadequate and is tied to the specific test and clinical context. |
| Positive-result interpretation appropriately qualified | PASS | Positive is not treated as a guarantee of response or automatic treatment eligibility. |
| Specimen adequacy appropriately qualified | PASS | Tissue adequacy is recognized without reproducing detailed assay-specific laboratory criteria outside the owning packages. |
| Companion diagnostics appropriately qualified | PASS | Concept introduced; detailed regulatory methodology excluded. |
| Tissue versus blood appropriately qualified | PASS | Blood-based molecular testing is not presented as a universal replacement for tissue testing. |

---

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Technical terms are introduced with explanations. |
| Patient-friendly wording | PASS | Question-based headings and short explanatory paragraphs are used. |
| Learning objectives satisfied | PASS | Objectives map directly to the clinical knowledge blocks. |
| Logical learning progression | PASS | The package moves from “why testing” to “which testing” to “what results mean” to “what happens next.” |
| Appropriate uncertainty communication | PASS | Predictive biomarkers, TMB, NGS, EBV, negative results and inadequate tests are qualified. |
| Avoids overpromising | PASS | No biomarker is described as guaranteeing response. |
| Treatment boundary visible | PASS | Testing is explicitly separated from treatment selection. |
| Practical usefulness | PASS | A dedicated patient-question block is included. |
| Common misconceptions addressed | PASS | Dedicated misconception section included. |
| Appropriate educational boundary | PASS | No attempt is made to interpret an individual's actual biomarker report or prescribe treatment. |
| Terminology consistency | PASS | PD-L1, MSI, MMR, MSI-H/dMMR, TMB, NGS, HER2 and CLDN18.2 are used consistently. |
| Patient safety | PASS | The package repeatedly directs individualized decisions to the cancer care team. |

---

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| CKO completed | PASS | 01_CKO.md produced. |
| Knowledge Passport completed | PASS | 02_KNOWLEDGE_PASSPORT.md produced. |
| Evidence Package completed | PASS | 03_PRIMARY_EVIDENCE_PACKAGE.md produced. |
| QA Report completed | PASS | This artifact completed. |
| Gold specification followed | PASS | Four-artifact structure preserved. |
| Approved Decision Batch respected | PASS | Locked scope is implemented without reopening decisions. |
| Source-first rule respected | PASS | Relevant project Source Files were searched and used before production. |
| Gold reference depth preserved | PASS | Artifacts are full-depth and not compacted relative to the supplied Gold references. |
| Artifact naming compliant | PASS | Standard four artifact names used. |
| Versioning compliant | PASS | Version 1.0.0 used for initial Gold release. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream links included. |
| Boundary ownership preserved | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP structure is explicit in the artifacts and final response. |
| Repository-ready structure | PASS | Four Markdown artifacts packaged in one PP directory and ZIP. |
| No silent scope expansion | PASS | Locked decisions were not expanded into new treatment or methodology ownership. |

---

# Clinical Safety Review

| Item | Result | QA Note |
|---|---|---|
| No individualized treatment recommendation | PASS | Package is testing-strategy education only. |
| No instruction to start/stop/change treatment | PASS | Explicitly excluded. |
| No individualized prognosis | PASS | Explicitly excluded. |
| No drug dosing | PASS | Explicitly excluded. |
| No toxicity management | PASS | Explicitly excluded. |
| No individualized biomarker interpretation | PASS | Dedicated biomarker packages retain ownership. |
| No unsupported biomarker threshold | PASS | Only source-supported framework is referenced; detailed thresholds are delegated. |
| No universal claim that NGS replaces other testing | PASS | NCCN hierarchy is preserved. |
| No universal claim that TMB is required | PASS | TMB is explicitly selected/context-dependent. |
| No universal claim that EBV testing is required | PASS | EBV is explicitly emerging/non-routine. |
| No claim that PD-L1 determines treatment by itself | PASS | Clinical-context dependence is repeatedly stated. |
| No claim that MSI/MMR replaces PD-L1 | PASS | Complementary relationship explicitly taught. |
| No claim that positive biomarker guarantees response | PASS | Predictive versus guaranteed response distinction preserved. |
| No claim that negative biomarker excludes all immunotherapy | PASS | Negative result is interpreted within biomarker and clinical context. |
| No claim that inadequate testing equals negative | PASS | Explicitly distinguished. |
| No claim that blood testing universally replaces tissue | PASS | Tissue/blood distinction preserved. |
| Appropriate referral to clinical team | PASS | Patient-facing questions and treatment-decision boundary included. |

---

# Educational Boundary Review

The Population Package remains within the locked atomic boundary.

## Included

- Purpose of immunotherapy biomarker testing.
- Predictive biomarker concept.
- PD-L1 testing role.
- MSI/MMR testing role.
- Complementary relationship between PD-L1 and MSI/MMR.
- Selected TMB and NGS context.
- EBV emerging status.
- HER2/CLDN18.2 interaction context.
- Timing and specimen considerations.
- Adequacy versus negative results.
- Conceptual tissue-versus-blood context.
- Companion-diagnostic concept.
- Patient-facing questions.
- Transition to downstream biomarker interpretation and immunotherapy application.

## Explicitly Excluded

- Detailed PD-L1 methodology/scoring.
- Detailed MSI/MMR methodology.
- Detailed TMB methodology.
- Detailed NGS methodology.
- Detailed EBV testing.
- Detailed HER2/CLDN18.2 testing.
- Molecular-report literacy.
- Variant interpretation.
- Germline testing algorithms.
- Drug-specific immunotherapy treatment.
- Dosing.
- Toxicity management.
- Response/resistance algorithms.
- Individualized treatment.
- Individualized prognosis.

The **Atomic Knowledge Principle** is preserved.

---

# Boundary QA

**Core =** immunotherapy biomarker-testing strategy, centered on PD-L1 and MSI/MMR, including why testing is performed, the complementary relationship of these biomarkers, selected TMB/NGS context, testing timing, specimen/adequacy concepts, result categories, multi-biomarker context, and the bridge from testing to downstream clinical application.

**Supporting =** high-level CPS/TAP and MSI/MMR method concepts, TMB/NGS concepts, companion-diagnostic context, tissue-versus-blood testing context, EBV as an emerging biomarker, HER2/CLDN18.2 as interacting treatment-relevant biomarkers, clinical-trial context, and patient-facing testing questions.

**Explicitly Excluded =** detailed PD-L1, MSI/MMR, TMB, NGS, EBV, HER2 and CLDN18.2 testing methodology; detailed molecular-report literacy; variant interpretation/classification; germline testing algorithms; immunotherapy drug mechanisms/regimens/dosing; toxicity management; response/resistance algorithms; individualized treatment; individualized prognosis.

**Delegated-to PP =** PP-0014, PP-0015, PP-0168, PP-0181, PP-0182, PP-0183, PP-0184, PP-0185, PP-0186, PP-0187, PP-0188, PP-0189, dedicated Companion Diagnostics and Liquid Biopsy/ctDNA packages, PP-0212, PP-0213, PP-0214, PP-0215, and downstream treatment/safety packages.

---

# Evidence Traceability QA

The major evidence claims are traceable to the supplied project Source Materials:

- **NCCN Gastric Cancer Version 2.2026** — universal MSI/MMR testing; PD-L1 testing; FFPE specimen; companion diagnostics; NGS; TMB; immunotherapy treatment contexts; broader biomarker framework.
- **NCI Treatment of Stomach Cancer** — biomarker testing as a way to help predict response to immunotherapy.
- **ACS Immunotherapy for Stomach Cancer** — patient-facing PD-L1 and MSI-H/dMMR treatment context.
- **ACS Chemotherapy for Stomach Cancer** — patient-facing examples of multi-biomarker treatment planning.
- **ESMO-ASCO Global Curriculum 2023** — professional molecular-testing and precision-oncology context.
- **NCI Genetics of Gastric Cancer / hereditary materials** — supporting context for appropriate genetic follow-up when indicated.

No silent substitution of external evidence was introduced.

---

# Gold Artifact Completeness Check

| Artifact | Present | Structural QA |
|---|---|---|
| 01_CKO.md | PASS | Metadata, objectives, scope, knowledge blocks, clinical importance, key concepts, misconceptions, key messages, Knowledge Graph and revision history present |
| 02_KNOWLEDGE_PASSPORT.md | PASS | Identity, classification, patient journey, runtime relevance, graph, clinical scope, sources, evidence classification, governance and version control present |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | PASS | Clinical question, intent, scope, sources, hierarchy, evidence matrix, evidence notes, claims summary, consistency review, gaps, update triggers, delegation, traceability and boundary verification present |
| 04_QA_REPORT.md | PASS | Four QA layers, clinical safety, educational boundary, governance, traceability, completeness and final decision present |

---

# Gold Depth Review

The package was reviewed against the project's Gold Depth rule and supplied Gold examples.

| Gold Requirement | Result | QA Note |
|---|---|---|
| No compaction | PASS | Sections were developed at full patient-facing depth. |
| No summarization in place of reasoning | PASS | Clinical distinctions and ownership boundaries are explicitly explained. |
| Evidence detail preserved | PASS | Evidence hierarchy, matrix, notes, claims, gaps and traceability are included. |
| Knowledge Graph depth preserved | PASS | Prerequisite, related and multiple downstream nodes are represented. |
| Patient-facing depth preserved | PASS | Dedicated explanatory blocks, misconceptions and patient questions are included. |
| QA depth preserved | PASS | Content, clinical, educational and governance layers are separately reviewed. |
| Boundary depth preserved | PASS | Core, Supporting, Explicitly Excluded and Delegated-to PP ownership is explicit. |

---

# Final Quality Decision

# PASS

PP-0192 satisfies the locked Gold Population Package production requirements and the approved/locked PP-0192 Decision Batch.

The package maintains the intended architecture:

**Foundational Immunotherapy + Biomarker Testing**

↓

**PD-L1 / MSI-MM​R / TMB / NGS dedicated testing packages**

↓

**PP-0192 — Biomarker Testing for Immunotherapy**

↓

**Biomarker-Specific Interpretation**

↓

**PP-0214 — MSI-H/dMMR Gastric Cancer and Immunotherapy**

**PP-0215 — PD-L1-guided Immunotherapy**

↓

**PP-0213 — Immune Checkpoint Inhibitors**

↓

**PP-0212 — Immunotherapy in Gastric Cancer**

The package does not duplicate substantive ownership of dedicated biomarker testing, molecular-report literacy, companion diagnostics, or immunotherapy treatment.

---

# Reviewer Notes

## Note 1 — Core testing hierarchy preserved

PD-L1 and MSI/MMR are presented as the central immunotherapy-relevant testing domains.

TMB and NGS are intentionally positioned as broader/selected molecular-testing considerations.

## Note 2 — Testing versus treatment boundary preserved

The package explains why a biomarker is tested and how the result contributes to decision-making, but does not prescribe treatment.

## Note 3 — Emerging biomarker boundary preserved

EBV is not elevated to routine status and remains delegated to the dedicated EBV package.

## Note 4 — Multi-biomarker context preserved

HER2 and CLDN18.2 may coexist in treatment planning but remain owned by their dedicated biomarker packages.

## Note 5 — Negative versus inadequate preserved

This distinction is explicitly maintained because it is important for patient safety and correct interpretation.

---

# Final Status

**PASS — GOLD — READY FOR INTEGRATION**
